Theralase Technologies (TSXV:TLT) Short Percentage of Float

View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Theralase Technologies's Short Percentage of Float

For the Medical Devices subindustry, Theralase Technologies's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's Short Percentage of Float Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's Short Percentage of Float falls into.

Save Embed

;

Save Embed

;

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

TLTFF:USA TTX:Germany

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.

Executives

Matthew Thomas Perraton	Director
Roger John Dumoulin-white	10% Security Holder, Director, Senior Officer
Kristina Maria Hachey	Senior Officer
Arkady Mandel	Senior Officer
Guy John Anderson	Director
Shawn Shirazi	Senior Officer